Tabirafusp tedromer

Phase 3Small molecule

Tabirafusp tedromer is one of 37 small molecule programs targeting Age-Related Macular Degeneration. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Age-Related Macular DegenerationActive, not recruiting

Diabetic Macular Edema (DME)Recruiting

Age-Related Macular DegenerationPhase 3

Active, not recruiting

Diabetic Macular Edema (DME)Phase 3

Recruiting

Competition

Competitive Landscape

43 competitors in Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Eylea

Regeneron

Approved

40 2

Zometa

Bayer Aspirin

Tecfidera

Plavix

Visudyne

BBausch Health Americas, Inc.

Approved

1 7

Lodosyn

LLaTonya J. Hickson

Approved

—8

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—9

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—10

Bendopa

MMerz North America, Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

Age-Related Macular Degeneration

NCT06556368

Q3 2029

Phase 3Recruiting

Diabetic Macular Edema (DME)

NCT07734844

Clinical

Trials by Indication[1]

Age-Related Macular Degeneration1 trial

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

Active, not recruiting·KKodiak Sciences Inc·Phase 3·NCT06556368·675 enrolled

Diabetic Macular Edema (DME)1 trial

A Randomized, Double-masked, Active-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Tedromer 5 mg Compared With Intravitreal Aflibercept 2 mg in Participants With Visual Impairment Secondary to Diabetic Macular Edema (DME) - ALTO

Recruiting·KKodiak Sciences Inc·Phase 3·NCT07734844·910 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Tabirafusp tedromer. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tabirafusp tedromer compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tabirafusp tedromer. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kodiak Sciences Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KKodiak Sciences Inc

Tabirafusp tedromer

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2029

Trials by Indication[1]

Age-Related Macular Degeneration1 trial

Diabetic Macular Edema (DME)1 trial

References

Drug Info

Quick Facts

Related News